- socially bharat
- December 13, 2024
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
Zug, Switzerland: Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent